Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Protocol Title: Clinical Evaluation of a Daily Wear Reusable Multifocal Optical Design in a 
Presby[CONTACT_402142]-6400  Version: 4.0                             Date: [ADDRESS_506625] 2020  
  Investigational Products: JJV Investigational senofilcon A Multifocal Contact [CONTACT_402143]:  Presby[CONTACT_19555], Multifocal, senofilcon A, Daily Wear, Reusable, Dispensing,   Statement of Compliance to protocol, GCP and applicable regulatory guidelines: This trial will be conducted in compliance with the protocol, ISO [ZIP_CODE],
1 the International 
Conference on Harmonization Good Clinical P ractice E6 ( ICH-GCP),2 the Declaration of 
Helsinki,3 and all applicable regulatory requirements. 
 Confidentiality Statement: This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, released or published without written approval from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by [CONTACT_19543], Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of [COMPANY_012] Vision Care, Inc. Any supplemental information that may be added to this document is also confidential and proprietary to [COMPANY_012] Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this document.    
CR-6400, v 4.0
 
Page 1 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
TABLE OF CONTENTS   
PROTOCOL TITLE, NUMBER, VERSION  ........................................................................... [ADDRESS_506626] Articles ............................................................................................ 26 
CR-6400, v 4.0
 
Page 2 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
6.2. Ancillary Supplies/Products ..................................................................................... [ADDRESS_506627] Articles  ................................................................................ 28  
7. STUDY EVALUATIONS  .............................................................................................. 29  
7.1. Time and Event Schedule ......................................................................................... 29  
7.2. Detailed Study Procedures ....................................................................................... 32  
VISIT 1 ........................................................................................................................... 32  
VISIT 2 ........................................................................................................................... 37  
VISIT 3 ........................................................................................................................... 41  
FINAL EVALUATION  .................................................................................................. 44  
7.3. Unscheduled Visits ................................................................................................... 44  
7.4. Laboratory Procedures ............................................................................................. 46  
8. SUBJECTS COMPLETION/WITHDRAWAL .............................................................. 46  
8.1. Completion Criteria  .................................................................................................. 46  
8.2. Withdrawal/Discontinuation from the Study ........................................................... 47  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_506628] QUALITY COMPLAINTS  .............. 49  
13. ADVERSE EVENTS  ................................................................................................... 50  
13.1.  Definitions and Classifications  ............................................................................. 50  
13.2.  Assessing Adverse Events .................................................................................... 52  
13.2.1.  Causality Assessment  .................................................................................... 53  
13.2.2.  Severity Assessment  ...................................................................................... 53  
13.3.  Documentation and Follow-Up of Adverse Events .............................................. 53  
13.4.  Reporting Adverse Events .................................................................................... 55  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 55  
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
 [ADDRESS_506629]  ............................................................................... 56  
CR-6400, v 4.0
 
Page 3 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
13.5.  Reporting of Pregnancy ........................................................................................ [ADDRESS_506630] KEEPI[INVESTIGATOR_1645]/ARCHIVING  ................................ 64  
15.1.  Electronic Case Report Form/Data Collection  ..................................................... [ADDRESS_506631]  ...................................................................................................... 65  
15.3  ClinicalTrials.gov  ................................................................................................. 65  
16. DATA MANAGEMENT ............................................................................................. 65  
16.1.  Access to Source Data/Document  ........................................................................ [ADDRESS_506632] (IEC/IRB) .......... [ADDRESS_506633] RETENTION ................................................................................ 70  
20. FINANCIAL CONSIDERATIONS  ............................................................................ 71  
21. PUBLICATION  ........................................................................................................... 71  
22. REFERENCES  ............................................................................................................ 71  
APPENDIX A:  ..... 72  
APPENDIX B: PATIENT INSTRUCTION GUIDE  ........................................................... 105  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  ....................................... 106  
CR-6400, v 4.0
 
Page 4 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX D: BINOCULAR OVER REFRACTION  ....................................................... 109  
APPENDIX E: PRESBY[CONTACT_19544]  ..................................... 110  
APPENDIX F: OCULAR DOMINANCE ............................................................................ 111  
APPENDIX G: LENS FITTING GUIDE  ............................................................................. 112  
APPENDIX H:  .................................... 114  
 DETERM INATION OF NEAR ADD  ............................................................... 115  
 NEAR lo gMAR VISUAL ACUITY MEASUREMENT PROCEDURE  .......... 121  
 LENS F ITTING CHARACTERISTICS  ............................................................ 124  
 SUBJEC T REPORTED OCULAR SYMPTOMS  ............................................. 130  
 FRONT AN D BACK SURFACE LENS DEPOSIT GRADING PROCEDURE
............................................................................................................................................... 132  
 DETERM INATION OF SPHEROCYLINDRICAL REFRACTIONS  ............. 138  
 BIOMIC ROSCOPY SCALE  ............................................................................. 145  
 KERAT OMETRY .............................................................................................. 151  
 DISTANC E AND NEAR VISUAL ACUITY MEASUREMENT PROCEDURE
............................................................................................................................................... 153  
 ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE  .. 158  
 WHITE L IGHT LENS SURFACE WETTABILITY  ........................................ 162  
 VISUAL A CUITY CHART LUMINANCE AND ROOM ILLUM INATION 
TESTING  .............................................................................................................................. 164  
APPENDIX I: COVID -19 RISK MITIGATION GUIDELINES  ........................................ 170  
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783]  ........................ 180  
 
TABLE OF CONTENTS   
Figure 1: Study Flowchart ...................................................................................................... 14  
 
TABLE OF CONTENTS   
Table 1: Planned Enrollment by [CONTACT_402144] ..................................................................... 24  
Table 2: Test Articles  .............................................................................................................. 26  
Table 3: Ancillary Supplies .................................................................................................... 27  
Table 4: Time and Events ....................................................................................................... 29  
Table 5: Disallowed systemic medications   ............................................................................ 48  
Table 6: Historical Studies Utilized for Sample Size Calculation  ...........................................57 
Table 7: Descriptive summary of Efficacy Endpoints Period 1 Only - 2-Week Follow -up ....58 
Table 8: Descriptive Summary of Safety Endpoints All Available Data ................................58 
Table 9: Degrees of Borrowing Historical Data by [CONTACT_402145] .........................59 
Table 10: Power Calculation by [CONTACT_27759]/Hypothesis A ssuming a Sample Size of 60 Subjects 
..................................................................................................................................................59 
CR-6400, v 4.0
 
Page 5 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PROTOCOL TITLE, NUMBER, VERSION  
Protocol Title: Clinical Evaluation of a Daily Wear Reusable Multifocal Optical Design in a 
Presby[CONTACT_402146]:  CR-6400    
Version: 4.0 
Date: [ADDRESS_506634] 2020    
 
SPONSOR NAME [CONTACT_93958] & Johnson Vision Care (JJVC)  
[ADDRESS_506635]  
Jacksonville, FL [ZIP_CODE]  
MEDICAL MONITOR 
Name:  [CONTACT_19617] R. Karkkainen, OD, MS, FAAO 
 
Address: [ADDRESS_506636], Jacksonville, [LOCATION_012] [ZIP_CODE] 
 
Email: [EMAIL_336] 
 
 
The Medical Monitor must be notified by [CONTACT_93822]/site by e -mail, fax, or 
telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contact[CONTACT_19546]. General study related questions should be directed towards your assigned clinical research associate.  
 The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.  
  
CR-6400, v 4.0
 
Page 6 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
SYNOPSIS  
Protocol Title  Protocol Title: Clinical Evaluation of a Daily Wear Reusable 
Multifocal Optical Design in a Presby[CONTACT_402147], [ADDRESS_506637] Article(s)  Investigational Products:  JJV Investigational Multifocal 
Contact [CONTACT_171176] A material.  
Wear and Replacement 
Schedules  Wear Schedule:  The Test lenses are used as daily wear 
reusable.   
 
Replacement Schedule:  The Test lens will be replaced  at the 
optimization visit.  The Test lenses will also be replaced 
when lost or damaged  
Objectives  The purpose of this study is to demonstrate that th e JJV 
Investigational senofilcon A Multifocal Contact [CONTACT_402148]100 (low add), FAL101(medium add) and FAL102 (high add), made in the Flexible Manufacturing Platform (FMP) meets the design validation requirements 
related to vision, ey e health and fit acceptance.   
Study Endpoints  Primary Endpoints  
• CLUE vision scores 
• LogMAR visual acuity scores  
• Unacceptable lens fit (Yes/No)  
• Grade 3 or Higher Biomicroscopy Findings (Yes/No) 
 Secondary Endpoints 
• Number of lenses needed to fit (optimize) the 
subject’s vision 
Other Endpoints 
• Lens Deposits 
• CLUE comfort/handling scores 
• PRO individual questions 
 
CR-6400, v 4.0
 
Page 10 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Study Design  This is a single -masked (partial), controlled, dispensing 
clinical trial.  A total of approximately  60 subjects will be 
targeted to complete  with a 1:1 allocation between strata 
(Hyperopes and Myopes).  S ubjects will be fit in  the study 
lens for approximately 2-4 days then return to  undergo 
optimization, if required and wear the optimized pair for 
approximately 2 weeks. The primary endpoints will be 
CLUE vision scores, logMAR visual acuity, biomicroscopy findings and  lens fit. 
 
See the flow chart at the end of the synopsis table for the schematic of the study visits and procedures of main 
observations ( Figure 1). 
Sample Size  A total of approximately [ADDRESS_506638] lens wearers in both eyes.  Additional information regarding the eligibility of the population can be 
found in the inclusion/exclusion cri teria outlined below.  
Eligibility Criteria  Potential subjects must satisfy all the following criteria to be 
enrolled in the study 
 Inclusion Criteria after Screening:  
  
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.  
2. The subject must appear able and willing to adhere to 
the instructions set forth in this clinical protocol.  
3. The subject must be at least [ADDRESS_506639] lens wearer in both eyes (i.e. wears lenses a minimum of [ADDRESS_506640] 6 hours per wear day, for 1 
month of more duration). 
6. The subject must either already be wearing a presby[CONTACT_171178] (e.g., reading spectacles over contact [CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.) or if not respond positively to at least one symptom on the “Presby[CONTACT_19552]”  (Appendix E) . 
CR-6400, v 4.0
 
Page 11 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
Inclusion Criteria after Baseline:  
7. The subject’s distance spherical equivalent refraction (vertex corrected if ≥ -4.25 D) must be in the range of 
-1.25 D to -5.75 D or +0.75 D to +3.[ADDRESS_506641]’s refractive cylinder must be ≤0.[ADDRESS_506642]’s ADD power must be in the range of +0.75 D to +2.[ADDRESS_506643] corrected visual acuity of 20/20
-3 or better in each eye.  
 Potential subjects who meet any of the following criteria will be excluded from participating in the study:   Exclusion Criteria after Screening:  
 
1. Currently pregnant or lactating. 
2. Any active or ongoing ocular or systemic allergies that may interfere with contact [CONTACT_13279].   
3. Any active or ongoing systemic disease, autoimmune 
disease, or use of medication, which may interfere 
with contact [CONTACT_13279]. This may include, but not be limited to , 
diabetes, hyperthyroidism, Sjögren’s 
syndrome, xerophthalmia, acne rosacea, Stevens -
Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis). 
4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal 
surgery, etc.). 
5. A history of amblyopia, strabismus or binocular vision abnormality. 
6. History of glaucoma, macular degeneration, recurrent corneal erosions, recurrent styes, herpetic keratitis, irregular cornea or pathological dry eye. 
7. Use of any of the following medications within 1 week prior to enrollment: oral retinoids, oral tetracyclines, 
oral phenothiazines, anticholinergics, corticosteroids.    
See Section  9.[ADDRESS_506644] 
clinical trial within 30 days prior to study enrollment.  
CR-6400, v 4.0
 
Page 12 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
10. Employee or immediate family member of an 
employee of clinical site (e.g., Investigator, 
Coordinator, Technician). 
11. Any known hypersensitivity or allergic reaction to 
Optifree®Replenish® multi-purpose care solution, 
sodium fluorescein or non-preserved rewetting drop solutions. 
 Exclusion Criteria after Baseline:  
12. Clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or  any other 
corneal or ocular abnormalities which would contraindicate contact [CONTACT_13279].  
13. Any current ocular infection or inflammation. 
14. Any current ocular abnormality that may interfere with contact [CONTACT_13279].  
 
Disallowed 
Medications/Interventions  Use of any prescription or over -the-counter (OTC) 
medications that may affect contact [CONTACT_13279].   
 See section 9.[ADDRESS_506645] (UADE), or any SAE where relationship to 
study agent cannot be ruled out, will result in stoppi[INVESTIGATOR_402135]. In the event of a UADE or SAE, t he Sponsor Medical Monitor may unmask 
the treatment regimen of subject(s) and may discuss this with the Principal Investigator [INVESTIGATOR_353849]. 
Ancillary Supplies/ Study -
Specific Materials  Rewetting  drops, lens cases, glass vials, saline, ETDRS light 
cabinet, distance (4M) logMAR charts, and Near logMAR 
charts. Optifree®Replenish® Contact [CONTACT_171179].  
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.  
 
CR-6400, v 4.0
 
Page 13 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS  
ADD   Plus Power Required For Near Use 
ADE   Adverse Device Effect  
AE   Adverse Event/Adverse Experience 
BCVA   Best Corrected Visual Acuity  
BSCVA  Best Spectacle Corrected Visual Acuity  
CFR   Code of Federal Regulations 
CLUE   Contact [CONTACT_402149]  
    
D   Diopter 
DMC   Data Monitoring Committee  
eCRF   Electronic Case Report Form  
EDC   Electronic Data Capture  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FDA   Food and Drug Administration 
GCP   Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountabi lity Act 
IB   Investigator’s Brochure 
ICF   Informed Consent Form 
ICH   International Conference on Harmonization 
IDE   Investigational Device Exemption  
IEC   Independent Ethics Committee 
IRB   Institutional Review Board  
ISO   International Organization fo r Standardization 
ITT   Intent- to-Treat 
JJVC   [COMPANY_012] Vision Care, Inc. 
LC   Limbus Center 
LogMAR  Logarithm of Minimal Angle of Resolution MedDRA
©  Medical Dictionary for Regulatory Activities  
MOP   Manual of Procedures 
NIH   National Institutes of Health  
OD   Right Eye 
OHRP   Office for Human Research Protections  
OHSR   Office for Human Subjects Research  
OS   Left Eye 
OU   Both Eyes 
PD   Protocol Deviation 
PHI   Protected Health Information  
PI   [INVESTIGATOR_402136]-6400, v 4.0
 
Page 15 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PIG   Patient Ins truction Guide 
PQC   Product Quality Complaint 
    
QA   Quality Assurance QC   Quality Control 
SAE   Serious Adverse Event/Serious Adverse Experience 
SAP   Statistical Analysis Plan  
SAS   Statistical Analysis System 
SD   Standard Deviation  
SOP   Standard Operating Procedure 
UADE   Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
VA   Visual Acuity  
                                
CR-6400, v 4.0
 
Page 16 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
better than 0.0 and the mean near logMAR acuity better than +0.[ADDRESS_506646] was permanently discontinued the study. The investigator considered the event to be not related to the study article/study procedure. Three epi[INVESTIGATOR_391343]. One subject had an ocular AE of non-
significant corneal foreign body of mild severity. The subject did not receive any treatment for this event. The event of non- significant corneal foreign body was reported as resolved and no 
action was taken with the study article. The investigator considered the event to be not related to the study article/study procedure. A second subject had two epi[INVESTIGATOR_1841] (one in each eye) of significant infiltrative event (SIE) of moderate sever ity. The subject received treatment for 
these events. Although the events were reported as resolved, the subject was permanently discontinued the study. The investigator considered the events to be related to the study article/study procedure.  
 
 was a dispensing crossover study on hyperope subjects and had a primary endpoint 
of subject vision response. There were [ADDRESS_506647]-0007 (10) 
Page 18 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
2.3. Hypotheses  
All the following co- primary hypotheses must be satisfied in order to meet the study objectives.  
 
Primary Hypotheses: 
1. After approximately 2- weeks of wear, the mean overall quality of vision score of the 
Test lenses will be statistically better than [ADDRESS_506648] lenses, the proportion (%) of eyes with at least one reported clinically significant slit-lamp finding (Grade 3 or 4) during the post- fit period will be 
significantly lower than 5%.    
7. When wearing the Test lenses, the proportion (%) of eyes with an unacceptable fit during the study will be statistically less than 5%.  
 
 
 
If all the primary hypotheses are met, the following secondary hypothesis will be tested. 
 
CR-6400, v 4.[ADDRESS_506649]-0007 (10) 
Page 21 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Secondary Hypothesis: 
1. The proportion of subjects who obtain the optimum lens pair in [ADDRESS_506650] 90%  using a 95% level of confidence. 
  
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
Healthy male and female subjects who are habitual soft contact [CONTACT_391358].  Subjects will be at least [ADDRESS_506651] satisfy all of the following criteria to be enrolled in the study:  Inclusion Criteria after Screening : 
  
1. The subject must read, understand, and sign the STATEMENT OF INFORMED 
CONSENT and receive a fully executed copy of the form. 
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.  
3. The subject must be at least [ADDRESS_506652] lens wearer in both eyes (i.e. wears lenses a minimum of [ADDRESS_506653] 6 hours per wear day, for 1 month of more duration). 
6. The subject must either already be wearing a presby[CONTACT_171178] (e.g., reading spectacles over contact [CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.) or if not respond positively to at least one symptom on the “Presby[CONTACT_391351]” (Appendix E).  
Inclusion Criteria after Baseline:  
 
7. The subject’s distance spherical equivalent refraction (vertex corrected if ≥-4.25 D) must be in the range of -1.25 D to -5.75 D or +0.75 D to +3.[ADDRESS_506654]’s refractive cylinder must be ≤0.[ADDRESS_506655]’s ADD power must be in the range of +0.75 D to +2.[ADDRESS_506656] corrected visual acuity of 20/[ADDRESS_506657]-0007 (10) 
Page 22 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study:   Exclusion Criteria after Screening:  
 
1. Currently pregnant or lactating. 
2. Any active or ongoing ocular or systemic allergies that may interfere with contact [CONTACT_13279].   
3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact [CONTACT_13279]. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, acne rosacea, Stevens -
Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis). 
4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, 
cataract surgery, retinal surgery, etc.).  
5. A history of amblyopia, strabismus or binocular vision abnormality. 
6. History of glaucoma, macular degeneration, recurrent corneal erosions, r ecurrent 
styes, herpetic keratitis, irregular cornea or pathological dry eye. 
7. Use of any of the following medications within 1 week prior to enrollment: oral retinoids, oral tetracyclines, oral phenothiazines, anticholinergics,  corticosteroids.  See 
Section 9.[ADDRESS_506658] clinical trial within 30 days prior to study enrollment. 
10.  Employee or imme diate family member of an employee of clinical site (e.g., 
Investigator, Coordinator, Technician). 
11. Any known hypersensitivity or allergic reaction to Optifree
®Replenish® multi-
purpose care solution, sodium fluorescein or non-preserved rewetting drop solutions. 
 Exclusion Criteria after Baseline:  
12. Clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or b ulbar injection, or any other corneal or 
ocular abnormalities which would contraindicate contact [CONTACT_13279]. 
13. Any current ocular infection or inflammation. 
14. Any current ocular abnormality that may interfere with contact [CONTACT_13279]. 
3.4. Enrollment Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject database and/or utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
 
CR-6400, v 4.[ADDRESS_506659]-0007 (10) 
Page 23 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Table 1: Planned Enrollment by [CONTACT_402150]  40 40 80 
Randomized   30 30 60 
Number of Enrolled per 
Site (min-max) Target 2-6 2-6  
 
4. STUDY DESIGN AND RATIONALE  
4.1. Description of Study Design  
The clinical study is a bilateral, single -masked (partial), single-arm, clinical trial. A total of 
approximately 60 eligible subjects  (30 myopes and 30 Hyperopes) will be targeted to complete 
the study.  
 The study begins with an initial visit, Visit 1 (Day 0), if a subject is found to meet all eligibil ity 
criteria, they will be fit with the study lens, in both eyes; otherwise the subject will be deemed ineligible and classified as a screen failure.  
 
If a subject is dispensed lenses at the initial visit, then two additional visits will be conducted. 
Visit 2 will occur 3 ± [ADDRESS_506660] reports unsa tisfactory vision or is unable to obtain 20/30 binocular  distance visual 
acuity with the study lense s. Subjects will return for Visit 3 (Final Evaluation) after 12±[ADDRESS_506661].  The final optimized lenses are dispensed for approximately 2 weeks of reusable wear which is the intended use cycle of the lens.   
4.3. Enrollment Target and Study Duration 
A total of approximately 80 eligible subjects will be enrolled  with 60 (30 myopes and 30 
hyperopes) targeted to complete the study.  The study is anticipated to last [ADDRESS_506662]-0007 (10) 
Page 24 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
5. TEST ARTICLE ALLOCATION AND MASKING  
5.1. Test Article Allocation  
The study lenses will be worn in a bilateral fashion using a single -arm design.  Due to the 
nature of the design no randomization is required.   
 
5.2.   Masking 
This is a single arm study and all subjects will be assigned to the same study lens. Subjects will be unaware  of the identity of the investigational product. Investigators and clinical site 
personnel involved in the data collection will not  be masked as to the identity of the 
investigational product.    Under normal circumstances, the mask should not be broken until all subjects have completed the study and the database is finalized. Otherwise, the mask should be broken only if specific emergency treatment/course of action would be dictated by [CONTACT_169762]. In such cases, the Investigator may, in an emergency, contact [CONTACT_7195].  In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatment assignment to the clinical site or Sponsor personnel.  
 
Subjects who have had their treatment assignment unmasked are expected to return for all remaining scheduled evaluations.  Subjects who are discontinued may be replaced.  
5.3.    Procedures for Maintaining and Breaking the Masking  
The test articles mask shall not be broken unless information concerning the lens type is necessary for the urgent medical treatment of a subject.  The Sponsor must be notified before 
the mask is broken.  When dispensing test articles, the following steps should be followed to maintain randomization codes: 
1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule/randomization scheme to obtain the test article assignment for that subject prior to dispensing 
2. Investigator or designee will record the subject’s number on the appropriate line of the randomization scheme if applicable  
3. Investigator or designee will pull the appropriate test articles from the study supply.  All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the “Dispensed” secti on 
CR-6400, v 4.[ADDRESS_506663]-0007 (10) 
Page 25 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Investigator’s discretion and based upon their 
findings on the measured visual acuity and /or 
over- refraction the investigator may make a 
modification . 
Up to two attempts at modification are 
permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide allowing for at least [ADDRESS_506664] letter OD, OS and OU.  
 
Note: The distance v isual acuity must be at 
least 20/30 OU for the lenses to be 
dispensed.   
1.31  Dispensing Criteria  The lenses will be dispensed for 2 -4 days. 
• Distance Snellen acuity equal to or 
better than 20/30 OU 
• Subject must indicate that the vision is 
acceptable.  
• Subject must indicate that the comfort of the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
1.[ADDRESS_506665] the following:  
• The lenses will be worn on a daily wear basis.   
CR-6400, v 4.[ADDRESS_506666]-0007 (10) 
Page 36 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Record any adverse events or medical history 
changes from the previous study visit.  
2.[ADDRESS_506667]’s compliance with 
wearing the study lenses.   
 Note: Subjects must have worn lenses for at 
least [ADDRESS_506668]’s distance and 
near vision with the lenses is acceptable.   
2.[ADDRESS_506669] on near vision under monocular and/or binocular 
conditions.     
2.[ADDRESS_506670] reports unsatisfactory vision, or 
is unable to obtain 20/[ADDRESS_506671]-0007 (10) 
Page 38 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  
If any of these slit lamp findings are Grade [ADDRESS_506672] a new pair of lenses that 
match the distance and ADD power of the 
lenses that were removed in Step 2.12 above.    
2.15 PRO (MRD)  
Questionnaire The subject will evaluate the vision 
characteristics, comfort characteristics, handling cha racteristics, and visual 
symptoms of the study lenses using the PRO 
questionnaire.   
2.[ADDRESS_506673] letter OD, OS and OU.  
  
Note: The distance visual acuity must be at 
least 20/30 OU for the lenses to be 
dispensed.   
2.17 Dispensing Criteria  The lenses will be dispensed for 10-14 days. 
• Distance Snellen acuity equal to or 
better than 20/30 OU 
• Subject must indicate that the vision is 
acceptable.  
• Subject must indicate that the comfort 
of the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
2.[ADDRESS_506674] the following:  
• The lenses will be worn on a daily wear basis.  
• OPTI-FREE
® Replenish® solution will be 
used in a rub regime to disinfect and store  
CR-6400, v 4.[ADDRESS_506675]-0007 (10) 
Page 40 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
7.3 and 7.9 EV (394 -597 lux). 
• Distance, HC -1 Chart luminance 
Acceptable Range 10.5- 10.7 EV (181-
208 cd/m2). 
• Guillon-Poling, Near Chart Luminance 
Acceptable Range 10.8 -11.1 EV (223-
274 cd/m2). 
•  
3.[ADDRESS_506676] the OD and OS results and distance visual acuity.   
Note: No lens changes are allowed based on 
the over-refraction.   Appendix D  
3.10  Lens Fit Assessment  Evaluate and grade lens centration, primary 
gaze movement,  upgaze movement and 
tightness (push-up test). 
 
• The subject should not proceed to wear 
the lenses if any of the following is observed: 
• presence of limbal exposure (appearance 
of clear cornea) in any gaze  
• presence of edge lift  
• presence of unacceptable movement (excessive or insufficient) in all three 
movement categories (primary gaze, upgaze, and push-up). 
 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p erform a slit -lamp 
evaluation, and complete the Final 
Evaluation form.    
3.[ADDRESS_506677] remove the study lenses and 
store in saline in a labeled glass vial.  
 
NOTE: Lenses do not need to be stored in a 
refrigerator.  
3.14  Biomicroscopy  Perform Biomicroscopy  OD and OS. FDA 
Slit Lamp Classification Scales * will be used 
to grade the findings.   
 
CR-6400, v 4.[ADDRESS_506678]-0007 (10) 
Page 43 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
8.2. Withdrawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons: 
• Subject death during the study period 
• Subject withdrawal of consent 
• Subject not compliant to protocol  
• Subject lost to follow -up  
• Subject no longer meets eligibility criteria (e.g. the subject becomes pregnant) 
• Subject develops significant or serious adverse events causing discontinuation of study 
lens wear  
• Subjects who have experienced a Corneal Infiltrative Event (CIE)  
• Investigator’s clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment)  
• Subject missed any  study visits  
• Subject not compliant with study lens wear schedule  
• Subject not successfully dispensed due to lack of efficacy and safety including poor vision, poor comfort or unacceptable fit  
For discontinued subjects, the Investigator will: 
• Complete the current visit (scheduled or unscheduled) 
• Complete the Final Evaluation, indicating the reason that the subject was discontinued from the study 
• Record the spherocylindrical refraction with best corrected distance visual acuity  
• Collect used test article(s) (worn or brought to the visit) from the subject and discard them, unless otherwise stated in Section 7.2 
• Collect all unused test article(s) from the subject  
 
An additional subject may be enrolled if a subject discontinues from the study prematurely.   In cases where a subject is lost to follow -up, every possible effort must be made to contact [CONTACT_402151] t he reason for discontinuation/withdrawal.  The measures taken to 
follow up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt.  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medications will be documented during screening and updated during the study.  Disallowed medications and therapi[INVESTIGATOR_402137].  See the Exclusion criteria for specific details.  
    
CR-6400, v 4.[ADDRESS_506679]-0007 (10) 
Page 47 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
11. STUDY TERMINATION 
 
The occurrence of one or more Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE), or any SAE where the relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_71151]. In the event of a [LOCATION_003]DE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled.  The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_402138]’s results are compromised.  JJVC reserves the right to terminate the study at any time for any reason. Additionally, the IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by [CONTACT_079] [INVESTIGATOR_71153], if in their opi[INVESTIGATOR_1649], after a di scussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.  
 JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part of the investigation presenting the risk, will be terminated as soon as possible.  Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as required by [CONTACT_35512]. 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of test articles after they have been released for clinical trial use.   
 Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical op erations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints: 
• Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient 
Reported Outcomes (PRO).” 
• Clinical test ar ticles that are stored improperly or damaged after receipt at the 
investigational site . 
• Lens replacements that occur due to drops/fall -outs. 
• Damage deemed by [CONTACT_35513], 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where 
there is no deficiency alleged by [CONTACT_423]. 
 Within [ADDRESS_506680]-0007 (10) 
Page 49 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use 
is not configured to send automatic notifications or when an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.    Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_253429]:  
• Date the complaint was received/recorded in the EDC System (Date of Sponsor Awareness) . 
• Who received the complaint. 
• Study number. 
• Clinical site information (contact [CONTACT_2300], site ID, telephone number). 
• Lot number(s). 
• Unique Subject Identifier(s). 
• Indication of who first observed complaint (site personnel or subject). 
• OD/OS indication, along with whether  the lens was inserted . 
• Any related AE number if applicable. 
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.). 
• Eye Care Provider objective (slit lamp) findings if applicable. 
• Confirmation of product availability for return (and tracking information, if available), 
or rationale if product is not available for return  
 
 
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or trained site personnel will follow Se ction 13 of this 
protocol. If the AE/SAE  was potentially the result of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.   
 In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the PQC forms will be marked “Intentionally Left Blank” or “ILB”.  Justification for ILB must be documented. 
13. ADVERSE EVENTS  
13.1. Definitions and C lassifications 
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational medical device.  
This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical dev ices1 
 
An AE includes any condition (including a pre-existing condition) that: 
CR-6400, v 4.[ADDRESS_506681]-0007 (10) 
Page 50 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
1. Was not present prior to the study, but appeared or reappeared following initiation of 
the study. 
2. Was present prior to the study, but worsened during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states. 
3. Pregnancy must be documented as an adverse event and must be reported to the clinical monitor and to the Sponsor immediately upon learning of the event. 
 Serious Adverse Event (SAE) – An SAE is any adverse event  that led to any of the following: 
• Death 
• Serious deterioration in the health of the subject that resulted in any of the following: 
• Life-threatening illness or injury 
• Permanent or persistent impairment of a body structure or a body function 
• Hospi[INVESTIGATOR_93790] 
• Medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function. 
• Chronic disease 
• Fetal distress, fetal death or a congenital physical or mental impairment of birth defect.  
 Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:  
• Microbial Keratitis (MK)  
• Iritis (including cells in the anterior chamber)  
• Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater  
• Central Corneal Opacity  
• Central Corneal Neovascularization  
• Uveitis 
• Endophthalmitis 
• Hypopyon 
• Hyphemia 
• Penetration of Bowman’s Membrane 
• Persistent Epi[INVESTIGATOR_32958] 
• Limbal cell Damage leading to Conjunc tivalization  
 Significant Adverse Events  – are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_402152], but  
not limited to the following: 
• Contact [CONTACT_35516] (CLPU) 
• Significant Infiltrative Events (SIE)  
• Superior Epi[INVESTIGATOR_32955] (SEALs)  
• Any Temporary Loss of > [ADDRESS_506682]-0007 (10) 
Page 51 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
• Other grade 3 or higher corneal findings, such as abrasions or edema 
• Non-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_71155] (EKC) 
• Asymptomatic Corneal Scar  
• Any corneal event which necessitates temporary lens discontinuation > 2 weeks 
 
Non-Significant Adverse Events  – are defined as t hose events that are usually asymptomatic 
and usually do not warrant discontinuation of contact [CONTACT_35517] a reduction in wear time.  However, the Investigator may choose to prescribe treatment as a precautionary measure.    Diagnoses and conditions that are considered Ocular Non- Significant Adverse Events include, 
but not limited to the following: 
• Non-significant Infiltrative Event (NSIE)  
• Contact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)  
• Superficial Punctate Keratitis (SPK)  
• Conjunctivitis: Bacteria l, Viral, Allergic  
• Blepharitis  
• Meibomianitis  
• Contact [CONTACT_32984]  
• Localized Allergic Reactions  
• Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary lens discontinuation < 2 weeks 
 
Adverse Device Effec t (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.  
NOTE 1: to entry:  This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or 
any malfunction of the investigational medical device. 
NOTE 2 to entry:  This definition includes any event resulting from use error or from 
intentional misuse of the investigational medical device.”[ADDRESS_506683] (UADE) – Any serious adverse effect on health or 
safety or any life -threatening problem or death caused by, or associated with, the test article, 
if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any other unanticipated serious problem associated with the test artic le that relates to the rights, safety 
and welfare of subjects.  
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
• Seriousness/Classifications (see definition in Section 13.1). 
CR-6400, v 4.[ADDRESS_506684]-0007 (10) 
Page 52 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
• Causality or Relatedness – i.e. the relationship between the test article, study treatment 
or study procedures and the adverse event (not related; unlikely related; possibly  
related; related - see definition in Section 13.2.1). 
• Adverse Event Severity – Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild; moderate; severe for all events - see definition in 
Section 13.2.2). 
• Outcome – not recovered or not resolved; recovering or resolving; recovered or 
resolved with sequelae; recovered or resolved; death related to adverse event; 
unknown. 
• Actions Taken – none; temporarily discontinued; permanently discontinued; other. 
13.2.1. Causality Assessment  
Causality Assessment – A determination of the relationship between an adverse event and the 
test article. The test article  relationship for each adverse event should be determined by [CONTACT_19575]: 
• Not Related - An adverse event that is not related to the use of the test article, study 
treatment or study procedures. 
• Unlikely Related – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not likely. 
• Possibly Related – An adverse event that might be due to the use of t he test article, or 
to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded . 
• Related – An adverse event that is listed as a possible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably explained by [CONTACT_4867], e.g. concomitant treatment of concomitant disease(s). The relationship in time is v ery 
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]- challenge and re- challenge. 
13.2.2. Severity Assessment  
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_423] . The assessment of 
severity is made irrespective of test article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale: 
• Mild – Event is noticeable to the subject, but is easily tolerated and does not interfere 
with the subject’s daily activities . 
• Moderate – Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily activities . 
• Severe – Event is intolerable, necessitates additional the rapy or alteration of therapy 
and interferes with the subject’s daily activities . 
13.3. Documentation and Follow- Up of Adverse Events  
The recording and documenting of adverse events (ocular and non- ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
CR-6400, v 4.[ADDRESS_506685]-0007 (10) 
Page 53 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the condition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse events at the discretion of the Investigator.  Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_71156]. He/she will complete the Adverse Event /eCRF.   
 Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for “serious adverse events” shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.    It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such documentation will include the following: 
• Adverse event (diagnosis not symptom). 
• Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.). 
• Date the clinical site was notified . 
• Date and time of onset . 
• Date and time of resolution . 
• Adverse event classification, severity, and relationship to test articles, as applicable. 
• Treatment regimen instituted, including concomitant medications prescribed, in accordance with applicable licensing requirements . 
• Any referral to another health care provider if needed. 
• Outcome, ocular damage (if any). 
• Likely etiology. 
• Best corrected visual acuity at the discovery of the event and upon conclusion of the 
event. 
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If  cultures are collected, the date of culture collection and 
laboratory utilized will be recorded.   Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse  events characterized as 
intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of relationship to the Test Article shall also be clearly documented.  
 
Subjects who present with an adverse event shall be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatment beyond licensure is required, the patient will 
CR-6400, v 4.[ADDRESS_506686]-0007 (10) 
Page 54 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
be referred to the appropriate health care provider. The Investigator will use his/her clinical 
judgment as to whether  a subject reporting with an adverse event will continue in the study. If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for discontinuation. The Investigator will also document the adverse event appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or study procedures, as of  the final study visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by [CONTACT_737]. Non- ocular adverse events that are 
not related to the test article, study treatment, or study procedures may be recorded as “ongoing” without further follow-up. 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery for any non- significant adverse event. In addition, 
a written report will be submitted by [CONTACT_079] [INVESTIGATOR_35451]/IRB according to their requirements (Section 13.4.2). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events  
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mail, fax, or telephone, but no later than 24 
hours following discovery of the event. The Investigator is obligated to pursue and obtain information requested by [CONTACT_35519]. All subjects experiencing a serious/significant adverse event must be followed up and all outcomes must be reported.  When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.  
 
In the event of a serious/significant adverse event, the Investigator must: 
• Notify the Sponsor immediately . 
• Obtain and maintain in the subject’s records all pertinent medical information and medical judgment for colleagues who  assisted in the treatment and follow -up of the 
subject. 
• Provide the Sponsor with a complete case history which includes a statement as to whether the event was or was not related to the use of the test article. 
• Notify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to national regulations. 
 
Unanticipated (Serious) Adverse Device Effect (UADE)  
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
CR-6400, v 4.[ADDRESS_506687]-0007 (10) 
Page 55 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
than [ADDRESS_506688] report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within [ADDRESS_506689].  Non-Serious Adverse Events  
All non-serious adverse events, including non- serious adverse device eff ects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth by [CONTACT_19581]/IRB. Each clinical site will refer to and follow any guidelines set forth by [CONTACT_19582].  The Sponsor will report applicable Adverse Events to the local health authorities according the written guidelines, including reporting timelines.  
13.4.3. Event of Special Interest  
None 
13.5. Reporting of Pregnancy 
 
Subjects reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their fetuses will not be monitored for study related purposes.   Pregnant participants are not discontinued from contact [CONTACT_71179], but due to general concerns relating to pregnancy and contact [CONTACT_19584]. Specifically, pregnant women are discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
14. STATISTICAL METHODS  
14.1. General Considerations  
Statistical Analysis will be undertaken by [CONTACT_35522]. A 
general description of the statistical methods to be implemented in this clinical trial is outlined below. More details will be included in the stand -alone Statistical Analysis Plan (SAP). The 
SAP will be developed and finalized prior to database lock.  
CR-6400, v 4.[ADDRESS_506690]-0007 (10) 
Page 56 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
4MCLM: Multi Cavity Lens Machine  
 
Summaries of efficacy data pooled across all the [ADDRESS_506691] shown that the average CLUE vision score of Hyperopes  is lower that of 
myopes.   
Table 7: Descriptive su mmary of Efficacy Endpoints Period [ADDRESS_506692] 
Deviation  Minimum  Maximum  
Distance VA (3m) -0.077 -0.100 0.1026 -0.320 0.560 
Intermediate  VA (64cm) -0.054 -0.060 0.1014 -0.300 0.360 
Near VAR (40cm) 0.077 0.060 0.1100 -0.260 0.460 
Hyperopes’ CLUE Vision score  47.71 48.07 17.514 10.22 93.50 
Myopes’ CLUE Vision score  56.[ADDRESS_506693] been 5 eyes with reported Grade 3 or higher SLFs.  
 
Table 8: Descriptive Summary of Safety Endpoints All Available Data  
Endpoint  Test  
n(%) 
Unacceptable lens fitting 1 (0.2) 
SLF Grade 3 + 5 (1.4) 
Total Eyes  (N) 350 
Total Subjects  175 
%= nx100/N  
 
Safety Analysis  
Our plan for  safety  analysis is to incorporate historical individual subject data from  the 6 
studies using power prior distributions in a Bayesian framework (see section 14.5). The level 
of influence of historical data on current  is determined  by a discounting factor a  constrained 
between 0 and 1 (0 ≤ a0≤ 1). a0 = 0 corresponds to no borrow ing of the historical data; while 
a0 = 1 corresponds to full borrowing (See section 14.5 for more details).  For this study we 
considered a low level of borrowing ranging by 0.[ADDRESS_506694] will be manufactured from the FMP platform; therefore, the borrowing strength is larger to len ses from the FMP platform. Furthermore, the TAM21 platform is 
considered equivalent with respect to lens performance and lenses from these platforms are 
CR-6400, v 4.[ADDRESS_506695]-0007 (10) 
Page 58 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
given the same borrowing strength as those from the FMP platform. While all historical studies 
used the lens in its final design, lenses made from the pi[INVESTIGATOR_402139] a borrowing 
strength of 10%.  
 
Table 9: Degrees of Borrowing Historical Data by [CONTACT_402153] ( a0) 
FMP 23 0.3 
TAM21 66 0.3 
Pi[INVESTIGATOR_402140] (SCLM, MCLM)  86 0.1 
 
 We calculated the required sample size with and without borrowing historical data . To achieve 
a minimum of 80% power with a 2- sided type I error rate of 5%, t he required sample size with 
no borrowing ( a0 = 0) was 120 subjects  (240 eyes) ; while the sample size with borrowing was 
60 subjects (120 eyes). The sample calculation in each scenario of borrowing was conducted 
using a Monte Carlo simulation of 1000 trials of samples of size 120 subjects (240 eyes) were drawn from a multivariate binary distribution assuming a  compound symmetric (CS) 
covariance structure between left and right eye from the same subject . Assuming a true 
proportion of eyes with grade 3 or higher SLFs of p=0.014 and a correlation of ρ=0.70 between 
left and right eye s. The same approach was considered for the proportion of eyes with 
unacceptable fitting assuming a true proportion of eyes with unacceptable fit  of p=0.01 and a correlation of ρ=0.[ADDRESS_506696] the efficacy hypotheses. No borrowing was considered for the primary efficacy analysis. Table 8 
summarize the  statistical power of a sample size of 60 subjects (120 eyes) for all endpoints.  
 
Table 10: Power Calculation by [CONTACT_27759]/Hypothesis A ssuming a Sample Size of 60 Subjects 
Endpoint  Borrowing  Hypothesis (H A) Power (%)  
Grade 3 or Higher SLFs  Yes pt < 0.05 80 
Unacceptable lens tit  Yes pt < 0.05 90 
VA Distance  No µt <  +0.10  > 99 
VA Intermediate  No µt < +0.17 > 99 
VA Near No µt < +0.17 > 99 
CLUE Vision (Hyperopes)  No µt ≥ 32 99 
CLUE Vision (Myopes)  No µt ≥ 40 99 
 
The power calculation of the efficacy analys es (CLUE and VA)  was conducted using historical 
data presented in Table [ADDRESS_506697]-0007 (10) 
Page 59 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
dropout rate is observed, then the targeted total enrollment number maybe be increased 
accordingly to ensure that a minimum of 60 subjects complete the study.  
14.3. Analysis Populations 
Safety Population: All subjects who were administered any test article excluding subjects who drop out prior to administering any test article. At least one observation should be recorded.  Per-Protocol Population:  All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by [CONTACT_35524] 
(Per-Protocol Population). Justification of excluding subjects with protocol deviations in the 
per-protocol population set will be documented in a memo to file. 
 
Intent-to-Treat (ITT) Population:  
All randomized subjects regardless of actual treatment  and subsequent withdrawal from study 
or deviation from protocol. At least one observation should be recorded. 
14.4. Level of Statistical Significance  
All planned analysis for this study will be conducted with an overall type I error rate of 5%.  
14.5. Primary Analysi s  
Primary Safety analysis:  Strategy of Incorporating Historical Data: Safety analysis will be performed by [CONTACT_402154] :  
. All these studies evaluated the same 
Test lens that was  built in different manufacturing platform s to the same in vitro product 
requirements and are also considered to be representative of final commercial production. The 
historical individual data will be incorporated using  is the pow er prior distribution (Ibrahim 
and Chen; 2000)
11.  
 Let (y, z) and (y
0, z0) denote the data from current study, and from historical data respectively , 
p the proportion of eyes with response [ADDRESS_506698] a power prior distribution for parameter of interests (p, ρ), we use the formula 
 
P(p, ρ | y0, z0, a0) ∝ L(p, ρ | y0, z0) a0 π0(p, ρ), 
 
where L(p, ρ | y0, z0)  ∝ P(y0, z0 | p, ρ) is the likelihood of ( p, ρ) based on the historical data 
and a0 is a discounting parameter constrained between 0 and 1. This parameter a 0 controls the 
amount of the historical data we are borrowing: a0 = 0 corresponds to no incorporation of the 
historical data , while a0 = 1 corresponds to full borrowing of historical data.  We set a0 = 0.[ADDRESS_506699] lens was made in FMP and TAM21 platforms and a0 = 0.[ADDRESS_506700]-0007 (10) 
Page 60 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
The posterior distribution of (p, ρ) given the current and historical data is  
 
P(p, ρ | y, z, y 0, z0, a0) ∝ L(p, ρ | y, z)L(p, ρ | y0, z0) a0 π0(p, ρ), 
 
where L(p, ρ | y, z)  ∝ P(y, z | p, ρ) is the likelihood of (p, ρ) based on the current data. 
  Primary Safety Analyses: Slit lamp finding grade 3 or higher and unacceptable lens fitting responses (yes/no) will be 
analyzed separately on the safety population using the Bayesian model described below. A sensitivity analysis will be conducted with no borrowing of historical data.  The Model: Let Y1 and Y2 denote the binary outcomes for the left and right eyes, respectively, when wearing the test lens. Considering the correlation, ρ, between Y1 and Y2, the distribution of the sum Y = Y1 + Y2 is obtained by [CONTACT_340377]. One of them follow a 
binomial distribution Bin(2, p) with mixing probability (1- 𝜌𝜌) and the other one follows a 
modified Bernoulli distribution MBern(p), taking value 0 and 2 rather than conventional 0 and 
1, with mixing probability p:  
P(Y = y| p, ρ) = (1- ρ)Bin(2, p)I
A1 +  ρMBern(p)I A2; 
where IA1 = {0, 1, 2} and I A2 = {0, 2}  
 To overcome the complexity of the mixture likelihood a latent variable Z
i, i = 1, 2 is introduced 
in the model to indicate in which component of the model the observation y i, i=1, 2, belongs 
to, that is,  
 
zi=�1,if the observation belong  to the MBern (p),
0,if the observation belong  to the Bin (2, p)   
 The joint distribution of the augmented data (Y
i, Zi), i=1, 2, is given by 
P(Y=yi, Z=zi| p,ρ) =   ρzipyizi/2(1−p)(2−yi)zi/2(1−ρ)1−zi�2
yi�pyi(1−zi)(1−p)(2−yi)(1−zi) 
 
The posterior distribution of (p,  ρ) given (y, z), (y 0, z0) and a 0 is 
 
P (p, ρ | | y, z, y 0, z0, a0) = P (y, z | p, ρ) P (y0, z0| p, ρ)a0 π0(p, ρ) 
 
where, π0 is joint prior distribution of (p, ρ). Here we assume p and ρ to be independent with a 
prior beta (α, β) for p and uniform (0,1) for ρ. Hence the joint distribution of (p, ρ) is given by 
π0 (p, ρ| α, β) ∝ pα -1(1-p)β-1. The Metropolis sampler algorithm as implemented in the 
SAS/STAT MCMC Procedure will be used to estimate the posterior distributions of the 
parameters ( p, ρ). Inferences will be made based on a posterior credible interval for the relevant 
parameters .  
 Hypothesis testing for safety endpoints will be conducted as follows: 
CR-6400, v 4.[ADDRESS_506701]-0007 (10) 
Page 61 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
• Slit Lamp Finding: the Null hypothesis will be rejected if the upper bound of the 2-
sided 95% credible interval of the posterior estimate of the proportion of eyes with 
grade 3 or higher SLFS is below 5%. 
 
• Unacceptable Len Fit:  The Null hypothesis will be rejected if the upper bound of the 
2-sided 95% credible interval of the  posterior estimate of the  proportion of eyes with 
unacceptable lens fitting is below 5%. 
If no SLF findings of Grade  3 or higher or unacceptable lens fit is observed, alternative analysis 
methods will be considered. More detai ls will be provided in the statistical analysis plan.  
Primary Efficacy Analyses: 
Efficacy analysis  will be conducted the Intent-to-Treat Population (ITT) without borrowing 
from historical data . A sensitivity analysis will be  performed by [CONTACT_402155]. The level of borrowing used in the safety analysis will be considered. Further 
sensitivity analys es on the Per -Protocol Population will also  be considered. 
 
CLUE Vision  
CLUE vision scores will be analyzed using a Bayesian normal random effects model  for 
repeated measures . The model will include baseline clue score, age, add power, gender, 
timepoint (3 -day and 2- week follow -up evaluations) and strata (Hyperopes and Myopes) and 
the interaction between timepoint and strata as fixed effects.  Site will be included as  a random 
effect. An unstructured (UN) covariance structure will be used to model the residual errors 
from measurements within the same subject across timepoints.  Heterogeneous residuals 
covariance structures (R -side) across strata will be considered when appropriate.  Non-
informative priors will be used for the unknown parameter. For the β coeff icients, independent 
non-informative priors N(0, 1000) will be used. For the variance of random effect 𝜎𝜎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 an 
independent non- informative conjugate prior inverse -gamma(0.001, 0.001) will be used. For 
the residual covariance structure an inverse-Wishart distribution will be used. Inferences will 
be carried out using the 95% posterior credible intervals for relevant parameters.  
 Hypothesis testing for CLUE Vision Scores endpoints will be conducted separately for each stratum: 
• Hyperopes: The Null hypothesis will be rejected if the lower bound of the 2- sided 95% 
credible interval of the clue vision posterior mean estimate is  above 32. 
 
• Myopes: The Null hypothesis will be rejected if the lower bound of the 2- sided 95% 
credible interval of the clue vision posterior mean estimate is above 40. 
 
Visual Acuity  
Binocular high luminance, high contrast (HLHC) visual acuity (logMAR) at the [ADDRESS_506702]-0007 (10) 
Page 62 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
repeated measures . The model will include strata (Hyperope and Myope), add power, age, 
gender, position (40cm, 64cm and 3m) and the interaction between strata and position as fixed 
effects. Site and will be included as a random effect. An unstructured (UN) covariance structure 
will be used to model the residual errors from measurements within the same subject across 
different positions. Heterogeneous residuals covariance structures (R -side) across position will 
be considered when appropriate. Non-informative priors will be used for the unknown 
parameter. For the β coefficients, independent non- informative priors N(0, 1000) will be used. 
For the variance of random effec t 𝜎𝜎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 an independent non- informative conjugate prior 
inverse-gamma(0.001, 0.001) will be used. For the residual covariance structure an inverse -
Wishart distribution will be used. Inferences will be carried out using the 95% posterior 
credible intervals for relevant parameters.  
 Hypothesis testing for visual acuity (logMAR) endpoints will be conducted separately for each position: 
• Distance: The Null hypothesis will be rejected if the upper bound of the 2- sided 95% 
credible interval the  binocular HLH C VA posterior mean estimate  is lower tha n +0.10 
logMAR. 
 
• Intermediate: The Null hypothesis will be rejected if the upper bound of the 2- sided 
95% credible interval the binocular HLHC VA posterior mean estimate is lower than 
+0.17 logMAR.  
• Near: The Null hypothesis will be rejected if the upper bound of the 2- sided 95% 
credible interval the binocular HLHC VA posterior mean estimate is lower than +0.[ADDRESS_506703] will be calculated as the original pair (2) plus all 
the required modifications to reach the optimal pair. In this study the minimum number of lenses per subject used would be [ADDRESS_506704] was able to achieve optimal lens pair in 4 lenses or less and 0 ot herwise. The 
binary response will be analyzed using Bayesian logistic regression random -effects model to 
estimate the proportion of eyes that reached optimal lens pair in 4 lenses or less.  The regression model will include strata (Hyperope and Myope), add  power, age, gender , event (fitting, 
optimization, 2 -week follow -up) and the interaction between strata by [CONTACT_15992] . Site will be 
included in the model as  a random effect. Non-informative priors will be used for the unknown 
parameter. For the β coefficients, independent non -informative priors N(0, 1000 ) will be used. 
For the variance of random effects of σ
site2 non-informative conjugate prior, inverse -gamma 
CR-6400, v 4.[ADDRESS_506705]-0007 (10) 
Page 63 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
(0.001, 0.001) will be used. Inferences will be made based on the posterior credible interval 
for the relevant parameters.  
 The null hypothesis will be rejected if the lower bound of the 2- sided 95% credible interval the 
proportion of subjects is above 90%.  
14.7. Other Exploratory Analyses  
Not Applicable 
14.8. Interim Analysis  
There will not be an interim analysis pe rformed on this study.  
14.9. Procedure for Handling Missing Data and Drop -Outs 
Missing or spurious values will not be imputed. The count of missing values will be included in the summary tables and listings.  
 Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. Past clinical trials don’t provide the evidence that subject dropout is systematic or not -at-
random. To evaluate the impact of missing data, sensitivity analysis will be conducted using fully Bayesian imputation by [CONTACT_402156]. 
14.10. Procedure for Reporting Deviations from Sta tistical Plan  
The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate from these analysis methods. If for any reason a change is made, the change will be documented in the study report along with a justification for the change.  
15. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING  
15.1. Electronic Case Report Form/Data Collection  
The data for this study will be captured on electronic case report forms (eCRFs) using an EDC system EDC system ( Bioclinica) . An authorized data originator will enter study data into the 
eCRFs using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and sent to JJVC for analysis.   
 External Data Sources for this study include: Not Applicable 
 The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_737]. The sponsor or sponsor’s representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.   
CR-6400, v 4.[ADDRESS_506706]-0007 (10) 
Page 64 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
Edit checks, electronic queries, and audit trails are built into t he system to ensure accurate and 
complete data collection. Data will be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and confidentiality. After the final databas e lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of the source data for the study.   The content and structure of the eCRFs are compliant with ISO14155:2011.
[ADDRESS_506707] should be ava ilable for the following:  
• subject identification  
• eligibility  
• study identification  
• study discussion 
• provision of and date of informed consent 
• visit dates  
• results of safety and efficacy parameters as required by [CONTACT_760] 
• a record of all adverse events  
• follow-up of adverse events 
• medical history and concomitant medication  
• test article receipt/dispensing/return records  
• date of study completion 
• reason for early discontinuation of test article or withdrawal from the study, if applicable  
 
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.  Adverse event notes must be reviewed and initialed by [CONTACT_737].  
15.3ClinicalT rials.gov  
Several prior studies have been performed with the investigational lenses therefore this study does not meet the definition of an early feasibility study and is required to be registered on ClinicalTrials.gov.  
16. DATA MANAGEMENT  
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial- related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
CR-6400, v 4.[ADDRESS_506708]-0007 (10) 
Page 65 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_506709] and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete test results and all data developed during this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.  
 Training on case report form completion will be provided to clinical site personnel before the start of the study. The Sponsor will review case report forms for accuracy and completeness remotely during the conduct of  the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.  
 Quality Assurance representatives from JJVC may visit clinical sites to review data  produced 
during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_71182]. 
17. CLINICAL MONITORING  
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_35453]’s designated clinical site personnel. The monitor’s responsibi lities will include: 
• Ensuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulatory requirements are maintained. 
• Ensuring the rights and wellbeing of subjects are protected. 
• Ensuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site personnel . 
• Ensuring that protocol deviations are documented with corrective action plans, as 
applicable. 
CR-6400, v 4.[ADDRESS_506710]-0007 (10) 
Page 66 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
• Ensuring that the clinical site has sufficient test article and supplies . 
• Clarifying questions regarding the study. 
• Resolving study issues or problems that may arise. 
• Reviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS  
18.1. Study-Specific Design Considerations  
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue participation. Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled. Only subjects who are fully able to understand the 
risks, benefits, and potential adverse events of the study, and provide their consent voluntarily will be enrolled.  
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_402141], the investigational plan, Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP) ,
[ADDRESS_506711] maintain 
clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP) ,[ADDRESS_506712] (IEC/IRB)  
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable): 
• Final protocol. 
• Sponsor-approved informed consent form (and any other written materials to be 
provided to the subjects) 
• Investigator’s Brochure (or equivalent information). 
• Sponsor-approved subject recruitment materials. 
• Information on compensation for study- related injuries or payment to subjects for 
participation in the study. 
• Investigator’s curriculum vitae, clinical licen ses, or equivalent information (unless not 
required, as documented by [CONTACT_8134]/IRB). 
• Information regarding funding, name [CONTACT_19618], institutional affiliations, other potential conflicts of interest, and incentives for subjects. 
CR-6400, v 4.[ADDRESS_506713]-0007 (10) 
Page 67 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
• Any other documents that the IEC/IRB requests to fulfill its obligation . 
 
This study will be undertaken only after IEC/IRB has given full approval of the final protocol,  
the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of this approval. This approval letter must be dated and must clearly identify the documents being approved.  During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
• Protocol revisions 
• Revision(s) to informed consent form and any other written materials to be provided to subjects 
• If applicable, new or revised subject recruitment materials approved by [CONTACT_1034] 
• Revisions to compensation for study- related injuries or payment to subjects for 
participation in the study 
• Investigator’s Brochure revisions  
• Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB) 
• Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB’s requirements 
• New information that may adversely affect the safety of the subjects or the conduct of the study 
• Major protocol deviations as required by [CONTACT_6179]/IRB  
• Report of deaths of subjects under the Investigator's care 
• Notification if a new Investigator is responsible for the study at the clinical site  
• Any other requirements of the IEC/IRB 
 For protocol revisions that increase subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).  At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing. 
 At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this notification must be retained at the clinical site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent  
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The consent form that is used must be approved by [CONTACT_19597]/IRB. The informed consent is in accordance with 
CR-6400, v 4.[ADDRESS_506714]-0007 (10) 
Page 68 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
principles that originated in the Declaration of Helsinki,[ADDRESS_506715]'s dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.  
18.5. Privacy of Personal Data 
The collection, processing and disclosure of personal data and medical infor mation related to 
the Study Subject, and personal data related to Principal Investigator [INVESTIGATOR_71158] (e.g., name, clinic address and phone number, curriculum vitae) is subject to compliance with the Health Information Portability and Accountability Act (HIPAA) in the [LOCATION_002]
[ADDRESS_506716] these data, to maintain the confidentiality 
of the person’s related health and medical information, to properly inform the concerned persons about the collection and processing of their personal data, to grant them reasonable  
access to their personal data and to prevent access by [CONTACT_35532].  All information obtained during the course of the investigation will be regarded as confidential. All personal data gathered in this trial will be treated in strictest confidenc e by [CONTACT_4718], 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.  The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.  These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance wit h applicable data privacy protection laws and regulations. 
The Sponsor ensures that the personal data will be: 
• processed fairly and lawfully. 
• collected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with th ese purposes. 
• adequate, relevant, and not excessive in relation to said purposes. 
CR-6400, v 4.[ADDRESS_506717]-0007 (10) 
Page 69 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
• accurate and, where necessary, kept current . 
 
Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries.  The subject has the right to request through the Investigator access to his personal data and the right to request rectification of any data that are not c orrect or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws and regulations.  Appropriate technical and organizational measures  to protect the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential. 
19. STUDY RECORD RETENTION  
In compliance with the ICH/GCP guidelines ,
2 the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected from each subject, as well as all 
study documents as specified in ICH/GCP2 and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.  
 Essential documents must be retained until at least two (2 ) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH  region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical development of the investigational product. These documents will be retained for a longer period if required by [CONTACT_253434]. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained.  If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_1640]. Under no circumstance shall the Investigator relocat e or dispose of any 
study documents before having obtained written approval from the Sponsor.  If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports.   
If the Investigator has a question regarding retention of study records, he/she should contact [CONTACT_19599]. 
CR-6400, v 4.[ADDRESS_506718]-0007 (10) 
Page 70 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
20. FINANCIAL CONSIDERATIONS  
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agreement will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC management representative prior to study initiation.  
 JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as: 
• Continuing an ineligible subject in the study. 
• Scheduling a study visit outside the subject’s acceptable visit range.  
JJVC reserves the right to withhold final remuneration until all study related activities have been completed, such as:  
• Query resolution. 
• Case Report Form signature. 
• Completion of any follow- up action items . 
21. PUBLICATION 
This study will be registered on ClinicalTrials.gov by [CONTACT_1034]. 
22. REFERENCES  
1. ISO [ZIP_CODE]:2011: Clinical Investigation of Medical Devices for Human Subjects — 
Good Clinical P ractice. Available at: https://www.iso.org/standard/[ZIP_CODE].html  
2. International Conference on Harmonization Good Clinical Practice E6 (ICH- GCP). 
Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy -
guidelines.html  
3. Declaration of Helsinki - Ethical principles for Medical Research Involving Human 
Subjects. Available at: https://www.wma.net/policies -post/wma -declaration -of-
helsinki-ethical-principles- for-medical-research-involving-human- subjects/  
4. [LOCATION_002] (US) Code of Federal Regulations (CFR). Available at: https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR  
5. Health Information Portability  and Accountability  Act (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html  
6. EU MDR 2017/[ADDRESS_506719]. A Comparison of Two 
Approaches for Selecting Covariance Structures in the Analysis of Repeated Measures. Communications in Statistics—Simulation and Computation. 
1998;27:591-604. 
8. Kenward MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood. Biometrics . 1997;53:983–997. 
 
   
CR-6400, v 4.[ADDRESS_506720]-0007 (10) 
Page 71 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
  
CR-6400, v 4.[ADDRESS_506721]-0007 (10) 
Page 72 of 180
JJVC CONFIDENTIAL
PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506722]-0007 (10) 
Page 73 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506723]-0007 (10) 
Page 74 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506724]-0007 (10) 
Page 75 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506725]-0007 (10) 
Page 76 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506726]-0007 (10) 
Page 77 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506727]-0007 (10) 
Page 78 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506728]-0007 (10) 
Page 79 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506729]-0007 (10) 
Page 80 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506730]-0007 (10) 
Page 81 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506731]-0007 (10) 
Page 82 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506732]-0007 (10) 
Page 83 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506733]-0007 (10) 
Page 84 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506734]-0007 (10) 
Page 85 of 180
JJVC CONFIDENTIAL

PRO SPECIFICATION Version 1 Final  2020-04-22Protocol 6400                 [COMPANY_012] Vision Care, Inc.                  Confidential [ADDRESS_506735]-0007 (10) 
Page 86 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX B: PATIENT INSTRUCTION GUIDE   
To be provided separately. 
CR-6400, v 4.[ADDRESS_506736]-0007 (10) 
Page 105 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
  
CR-6400, v 4.[ADDRESS_506737]-0007 (10) 
Page 106 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX D: BINOCULAR OVER REFRACTION 
 
 
 
 
 
 
          
  
  
 
 
 
 
  
 
    
CR-6400, v 4.[ADDRESS_506738]-0007 (10) 
Page 109 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
APPENDIX E: PRESBY[CONTACT_402157]-6400, v 4.[ADDRESS_506739]-0007 (10) 
Page 110 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX F:  OCULAR DOMINANCE  
 
CR-6400, v 4.[ADDRESS_506740]-0007 (10) 
Page 111 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX G: LENS FITTING GUIDE  
CR-6400, v 4.[ADDRESS_506741]-0007 (10) 
Page 112 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6400, v 4.[ADDRESS_506742]-0007 (10) 
Page 113 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DETERM INATION OF NEAR ADD 
 
  
CR-6400, v 4.[ADDRESS_506743]-0007 (10) 
Page 115 of 180
JJVC CONFIDENTIAL

Title:                          Determination of Near Addition 
Document Type:       Work Instructions 
Document Number:  CTP-2005 Revision Number:  4 
Page 4 of 5 6 If the tentative ADD is too strong (too much plus), ask the pat ient to place the 
near point card at the desired test distance. Place -0.25D in front of both eyes 
(using +/- 0.25D flippers or loose trial lenses) and ask him/her to compare the 
tentative ADD with and without the -0.25D. If adding -0.25D does not reduce 
clarity add the -0.25D to the tentativ e ADD and repeat the procedure. Continue 
to add -0.25D until the patient begins to have a reduction in clarity.  
 
With the additional power in place, measure the range of clear focus (i.e., clear 
focus zone). 
 
Repeat this step until the near point is approximately midway in the clear 
zone.  If the desi red test distance is…  Then 
Approxima tely midway within 
the clear focus zone  No further adjustments 
are necessary.  
Near the edge of the clear focus 
zone closest to the patient  Add -0.25D and measure 
the range of clear focus 
again.  
Near the edge of the clear focus 
zone furthest from the pa tient Add +0.25D and measure 
the range of clear focus 
again.  
7 If the tentative ADD is too weak  (too much minu s), ask the patient to place 
the near point card at the desi red test distance. Place +0.25D in front of both 
eyes (using +/ - 0.25D flippers or loose trial lenses) and ask him/her to 
compare the tentativ e ADD with and without the +0.25D. If adding +0.25D 
improves clarity (visual acuity), add the +0.25D to the tentat ive ADD and 
repeat the procedure.  Continue to add +0.25D until no more improvement in near visual acuity is achieved at the desired test dist ance.  
NOTE:  Be careful to question the pat ient to en sure that he/she is 
actually seeing an improvement in visual  acuity.     
With this in place, measure the range of clear focus for the near point card.  
 
Repeat this step un til the near point is approximately midway within the 
clear zone.  If the desired test distance is…  Then 
Approximate ly midway within 
the clear focus zone  No further adjus tments 
are necessary.  
At the edge of the clear focus 
zone closest to the patient  Add -0.25D and measure 
the range of clear focus 
again.  
At the edge of the clear focus 
zone furthest from the patient  Add +0.25D and measure 
the range of clear fo cus 
again.  
 
5. GRADING SCALE  
 
• ADD Power: Diopters (0.25D increments)  
• Distance tested and range of clear focus: cm (one unit increments) 
• Visual Acuity: Snellen  
 
 
       
 
CR-6400, v 4.[ADDRESS_506744]-0007 (10) 
Page 119 of 180
JJVC CONFIDENTIAL
Title:                          Determination of Near Addition 
Document Type:       Work Instructions 
Document Number:  CTP-2005 Revision Number:  4 
Page 5 of 5 6. REFERENCES  
 
• Carlson, NB, et. al. ( 1996) Fused Cross Cylinder, in Clinical Procedures for  Ocular Examination 2nd ed.  
(Appleton and Lange, Samford CT): 188- 190. 
• Grosvenor, TP (1982). The Binocular Vision Examination, Chapter 9 in Primary Care Optometry: A 
clinical manual. Grosvensor, TP (Pr ofessional Press, Chicago): 189-200. 
• Michaels, DD (1985) Refracting the Aging Eye, Chapter 20 in Visual  Optics and Refraction. A clinical 
approach.  Michaels, DD.  (Mosby, St.Louis): 414 -425. 
• Patorgis, CJ (1987).  Presby[CONTACT_19555], Chapter 8 in Diagnosis and Mana gement in Vision Care.  Amos J 
(Butterworths, [LOCATION_011]): 226 -235. 
 
7. TRAINING REQUIREMENTS  
 
       The training requirement for this document is  “Read Only.” 
  
 
CR-6400, v 4.[ADDRESS_506745]-0007 (10) 
Page 120 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2006, NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE  
  
CR-6400, v 4.[ADDRESS_506746]-0007 (10) 
Page 121 of 180
JJVC CONFIDENTIAL
Title:                          Near LogMAR Visual Acuity Measurement Procedure  
Document Type:       Work Instructions  
Document Number:  CTP-2006 Revision Number:  [ADDRESS_506747],   
to 50cm, from the chart (depending on what 
improves their vision) and repeat the step 2,, unless 
the study protocol states t hat this is not allowed .   
Record the new test distance in the CRF  and proceed 
to the next step . 
Can’t correctly read 
3 or more letters after moving the 
chart to 33 and/or [ADDRESS_506748] the number of letters missed in the top line 
proceed to step 6 .  If using EDC, y ou will need to 
answer an automated query. 
 
3 It is required that responses are recorded starting from a line w here no letters 
are missed.   For lines where no letters are missed, check the “ None” box in 
EDC next to that line of letters  (or record “0” missing next to the line if 
recording on paper) .  After the subject passes the first attempted line,  instruct 
the subject to continue reading lines down through the chart. For each line 
read, line through letters that are missed by [CONTACT_402158] . For each subsequent line read, check th e 
box next to each letter missed by [CONTACT_423], or check the “None” box if no 
letters are m issed.  NOTE: If recording on paper, place a line through each 
letter missed, or mark a line through the entire row of letters if they are 
all missed,  and then record th e number of letters mis sed (0 to 5) next to 
each line.    
[ADDRESS_506749] says he/she cannot see the next line, en courage him/her to take 
his/her best guess . 
[ADDRESS_506750] mis ses three or more letters  on a single 
line.  (NOTE:  If the subject m isses three letters on a li ne, and there are 
still letters that they haven’t  attempted to read  have the subject attemp t to 
read the remaining letters and record the results .) Otherwise, c ontinue to 
encourage the subjects to keep reading the next line below till reaching the bottom line. If subjects correctly read all [ADDRESS_506751] from the chart . 
6 Repeat procedure with the same eye or complete the other eye the appropriate 
number of times,  per protocol requireme nt. 
 
5. REFERENCES  
 
• Guillon, M., D.P. Lydon, and R.T. Solman, Effect of target contrast and luminance on soft contact [CONTACT_402159]. Curr Eye Res, 1988. 7(7): p. 635- 48. 
 
6. 
DATA MANAGEMENT  
 
The electronic data capture system will automatically convert logMAR visual acuity if the chart is used at a distance other than what it was designed for.  The formula to compute logMAR score at  a different distance 
other than the chart specified distance is:   LogMAR2 = LogMAR1 + log10(D1/D2),  
 
7. 
TRAINING REQUIREMENT  
 The training requirement for this document is “Read Only.”   
CR-6400, v 4.[ADDRESS_506752]-0007 (10) 
Page 123 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2008, LENS FITTING CHARACTERISTICS  
  
CR-6400, v 4.[ADDRESS_506753]-0007 (10) 
Page 124 of 180
JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics  
Document Type:       Work Instructions  
Document Number:  CTP-2008 Revision Number:  [ADDRESS_506754]-0007 (10) 
Page 128 of 180
JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics  
Document Type:       Work Instructions  
Document Number:  CTP-2008 Revision Number:  [ADDRESS_506755]-0007 (10) 
Page 129 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2009, SUBJECT REPORTED OCULAR SYMPTOMS  
  
CR-6400, v 4.[ADDRESS_506756]-0007 (10) 
Page 130 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2011, FRONT AND BACK SURFACE LENS DEPOSIT GRADING 
PROCEDURE  
  
CR-6400, v 4.[ADDRESS_506757]-0007 (10) 
Page 132 of 180
JJVC CONFIDENTIAL
Page 2 of 5 
 • Attachment B :  Examples of the deposition grading scale.  
 
 
REFERENCES  
• Mandell, R.B. (1988). Contact [CONTACT_402160]. Charles C. Thomas, Springfield, IL, pp 628 -
643. 
     
• Minno, G.E., Eckel, L., Groemminger, S., Minno, B., & Wrzosek , T. (1991). Quantitative 
Analysis of Protein Deposits on Hydrophilic Soft Contact [CONTACT_32993]: I. Comparison to Visual Methods of Analysis. II. Deposit Variation among FDA Lens Material Groups. Optometry and Vision Science, 68 (11): 865- 872. 
 
 
TRAINING     The training requirement for this document is  “Read Only.”  
REQUIRE - 
MENTS 
 
 
 
CASE REPORT   See Attachment C  
FORM MODULE  
   
 
 
CR-6400, v 4.[ADDRESS_506758]-0007 (10) 
Page 134 of 180
JJVC CONFIDENTIAL
Page 3 of 5 
 Attachment A   
 
NOTE:  The deposition need not be uniform in size.  The total area of deposition on the lens is determined by 
[CONTACT_402161] l regions with debris together.   
 
 
      
 
  
CR-6400, v 4.[ADDRESS_506759]-0007 (10) 
Page 135 of 180
JJVC CONFIDENTIAL
Page 4 of 5 
 Attachment  B 
 
a) Grade 1:  1 – 5% lens area        b) Grade 2:  6 - 15% lens area  
       
               
  
 
c) Grade 3:  16 - 25% lens area        d) Grade 4:  ≥ 26% lens area   
       
                 
   
CR-6400, v 4.[ADDRESS_506760]-0007 (10) 
Page 136 of 180
JJVC CONFIDENTIAL
Page 5 of 5 
 Attachmen t C 
 
 
 
  OD         OS 
 
SURFACE DEPOSITS : 
 
1. Front Surface Deposits :  
1   None 4 Moderate  1   None 4 Moderate 
2   Slight 5 Severe  2   Slight 5 Severe 
3    Mild    3    Mild   
 
2. Back Surface Deposits : 
1   None 4 Moderate  1   None 4 Moderate 
2   Slight 5 Severe  2   Slight 5 Severe 
3    Mild    3    Mild   
 
Scale: 
Grade 0 None No deposition.  
Grade 1 Slight Deposition, which occupi[INVESTIGATOR_014] 1 -5% of the lens surface area.  
Grade 2  Mild Deposition, which occupi[INVESTIGATOR_014] 6 -15% of the lens surface area.  
Grade 3 Moderate  Deposition, which occupi[INVESTIGATOR_014] 16 -25% of the lens surface area.  
Grade 4  Severe Deposition, which occupi[INVESTIGATOR_014] 26% of the lens surface area.  
     
 
CR-6400, v 4.[ADDRESS_506761]-0007 (10) 
Page 137 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2016, DETERMINATION OF SPHEROCYLINDRICAL REFRACTIONS  
  
CR-6400, v 4.[ADDRESS_506762]-0007 (10) 
Page 138 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
CTP-2018, BIOMICROSCOPY SCALE  
  
CR-6400, v 4.[ADDRESS_506763]-0007 (10) 
Page 145 of 180
JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 KERAT OMETRY 
  
CR-6400, v 4.0
 
Page 151 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DISTANCE AND NEAR VISUAL ACUITY MEASUREMENT 
PROCEDURE  
  
CR-6400, v 4.0
 
Page 153 of 180
JJVC CONFIDENTIAL

Title: Distance and Near Visual Acuity Evaluation  
Document Type:  Clinical Test Procedure  
    
 
Page 4 of 4 
  
CR-6400, v 4.0
 
Page 157 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 ETDRS DI STANCE VISUAL ACUITY MEASUREMENT PROCEDURE  
  
CR-6400, v 4.0
 
Page 158 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
WHITE LI GHT LENS SURFACE WETTABILITY  
  
CR-6400, v 4.0
 
Page 162 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 VISUAL ACUI TY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING  
  
CR-6400, v 4.0
 
Page 164 of 180
JJVC CONFIDENTIAL

  
Title: Visual Acuity Chart Luminance and Room Illumination Testing  
Document Type:  Work Instructions  
    
Page 1 of 5 
 
CR-6400, v 4.0
 
Page 165 of 180
JJVC CONFIDENTIAL

  
Title: Visual Acuity Chart Luminance and Room Illumination Testing  
Document Type:  Work Instructions  
    
 
Page 2 of 5 
  
  
 
     
CR-6400, v 4.0
 
Page 166 of 180
JJVC CONFIDENTIAL

  
Title: Visual Acuity Chart Luminance and Room Illumination Testing  
Document Type:  Work Instructions  
    
 
Page 4 of 5 
  
CR-6400, v 4.0
 
Page 168 of 180
JJVC CONFIDENTIAL

  
Title: Visual Acuity Chart Luminance and Room Illumination Testing  
Document Type:  Work Instructions  
    
 
Page 5 of 5 
  
CR-6400, v 4.0
 
Page 169 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX I: COVID-19 RISK MITIGATION GUIDELINES  
  
CR-6400, v 4.0
 
Page 170 of 180
JJVC CONFIDENTIAL

Title: Guidelines for COVID-19 Risk Mitigation  
Document Type:  Work Instruction  
Document Number:  VWI-0081 Revision Number:  1 
 
Page 1 of 9 1.0 PURPOSE  
The purpose of this document is to provide guidelines for  the re-opening or initiation of clinical study sites 
in the [LOCATION_002] (US) participating in [COMPANY_012] Vision Care, Inc. ( JJVCI) clinical studies during 
the COVID- 19 pandemic.   
2.0 SCOPE 
This document provides  guidelines  for [COMPANY_012] Vision Care ( JJVCI) to address the potential risks 
from COVID -[ADDRESS_506764]  
from the date of approval through the date of retirement of this Work Instruction.  At a minimum , this Work 
Instruction will be reviewed and updated on a quarterly basis, as appropriate.  
NOTE:  Sites outside of the US will be evaluated on a site by [CONTACT_402162].  
3.0 DEFINITIONS  
 
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, [LOCATION_012]. Its goal is to maintain and enhance excellence in optometric 
practice, by [CONTACT_93949]. The AAO holds an annual 
meeting, publishes a monthly scientific journal, gives credentials to optometrists through the fellowship 
process and publishes position statements.  
 
American Optometric Association ( AOA): The American Optometric Association, founded in 1898, is 
the leading  authority on quality care and an advocate for our nation's health, representing more than 44,000 
doctors of optometry (O.D.), optometric professionals, and optometry students. Doctors of optometry take a leading role in patient care with respect to eye and vision care, as well as general health and well -being. As 
primary health care providers, doctors of optometry have extensive, ongoing training to examine, diagnose, treat and manage ocular disorders, diseases and injuries and systemic diseases that manifest in the eye. The American Optometric Association is a federation of state, student, and armed forces optometric 
associations. Through these affiliations, the AOA serves members consisting of optometrists, students of 
optometry, paraoptometric assistants  and technicians. The AOA and its affiliates work to provide the public 
with quality vision and eye care.  
Center for Disease Control ( CDC): The Centers for Disease Control and Prevention is a national public 
health institute in the [LOCATION_002]. It is a U nited States federal agency, under the Department of Health 
and Human Services, and is headquartered in Atlanta, Georgia.    
COVID-19: Current outbreak of respi[INVESTIGATOR_19538] a novel coronavirus. The virus has been 
named “SARS -CoV-2” and the disease it causes has been named “Coronavirus Disease 2019” (COVID -
19).  
Clinical Study:  Voluntary research studies conducted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapi[INVESTIGATOR_014], or new ways of using existing treatments. May also be called clinical trials, studies, research, trials, or protocols.  
Clinical Study Site: Location where a clinical study is conducted, such as a doctor’s office, university, or 
laboratory. Clinical studies are co nducted by [CONTACT_35583](s) responsible for the 
conduct of the clinical study at a study site. If a study is conducted by a team of individuals, the Investigator is the responsible leader of the team and may be called the Principal Inves tigator.  
Clinical Operations Manager  (COM): The [COMPANY_012] Vision Care ( JJVCI) individual 
responsible for the overall management of a clinical trial.  
CR-6400, v 4.0
 
Page 171 of 180
JJVC CONFIDENTIAL

7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU 9:, 5HYLVLRQ1XPEHU
3DJHRI  0RQLWRU$QLQGLYLGXDOGHVLJQDWHGWRRYHUVHH WKHSURJUHVVRIDFOLQLFDOVWX G\DQGHQVXUHWKDWLWLV
FRQGXFWHGUHFRUGHGDQGUHSRUWH GLQDFFRUGDQFHZLWKWKHSURWRF RO6WDQGDUG2SHUDWLQJ3URFHGXUHV623V
*RRG&OLQLFDO3UDFWLFH*&3DQG DSSOLFDEOHUHJXODWRU\UHTXLUH PHQWV
0HGLFDO6DIHW\2IILFHU062 3K\VLFLDQZKRKDVSULPDU\DFFRXQWDELOLW\LQWKHLUSURGXFWSRUW IROLRIRU
SURGXFWKHDOWKDQGVDIHW\DQGZKRVHUYHVDVDQLQGHSHQGHQWPHG LFDOYRLFHIRUSDWLHQWVDIHW\

6DIHW\0DQDJHPHQW7HDP607$FURVVIXQFWLRQDOFROODERUDWLYHWHDPUHVSRQVLEOHIRUUHYLHZ 
DVVHVVPHQWDQGHYDOXDWLRQRIPHG LFDOVDIHW\GDWDDULVLQJIURPD Q\VRXUFHWKURXJKRXWWKHSURGXFWOLIHF\FOH
*8,'$1&()25678'<'2&80(176
,QDOLJQPHQWZLWKUHFHQWKHDOWKDXWKRULW\JXLGDQFH--9&,LVSU RYLGLQJUHFRPPHQGDWLRQVIRUVWXG\UHODWHG
PDQDJHPHQWLQWKHHYHQWRIGLVU XSWLRQWRWKHFRQGXFWRIWKHFOL QLFDOVWXG\7KLVJXLGDQFHGRHVQRWVXSHUVHGH
DQ\ORFDORUJRYHUQPHQWUHTXLUH PHQWVRUWKHFOLQLFDOMXGJHPHQW RIWKHLQYHVWLJDWRUWRSURWHFWWKHKHDOWKVDIHW\
DQGZHOOEHLQJRISDUWLFLSDQWVDQGVLWHVWDII,IDWDQ\WLPH DSDUWLFLSDQW¶VVDIHW\LVFRQVLGHUHGWREHDWULVN
VWXG\LQWHUYHQWLRQZLOOEHGLVFRQWLQXHGDQGVWXG\IROORZXSZL OOEHFRQGXFWHGDVRXWOLQHGLQWKHSURWRFRO
'XULQJWKH&29,'SDQGHPLFWKHDGGLWLRQDOULVNVOLVWHGEHORZ QHHGWREHFRQVLGHUHGIRUVWXG\SDUWLFLSDQWV
DQGVWXG\SHUVRQQHO
$GGLWLRQDO5LVNV5HODWHGWRWKH&29,'3DQGHPLF
x7KHSRVVLEOHWUDQVPLVVLRQRIWKH&RURQDYLUXVLQIHFWLRQDQGFRQV HTXHQWFRPSOLFDWLRQVEH\RQGWKH
ULVNRIDGYHUVHHYHQWVGXHWRWKHLQYHVWLJDWLRQDOGHYLFHDQGRU SURFHGXUHV
x7KHULVNPD\EHKLJKHULQDQRSWRPHWULFFOLQLFDOVWXG\EHFDXVH RIWKHFORVHFRQWDFWWKHVXEMHFWZLOO
KDYHZLWKKHDOWKFDUHSURIHVVLRQDOVGXULQJWKHSURFHGXUHVDQGD VVHVVPHQWVVLQFHWKHLQYHVWLJDWRU
PXVWPDNHWKHPHDVXUHPHQWVFOR VHWRWKHVXEMHFW¶VIDFHDQGLQ DGGLWLRQWKHQHHGIRUPXOWLSOH
IROORZXS YLVLWVH[DPV ZKLFK PD\ H[SRVH WKH VXEMHFW WR RWKHU SD WLHQWV DQGRU KHDOWKFDUH
SURIHVVLRQDOVZKRPLJKWEHWUDQVPLWWLQJWKHYLUXVHYHQLIWKH\ GRQRWKDYHV\PSWRPV
x3RWHQWLDOGLVUXSWLRQVWRWKHVW XG\PD\EHQHFHVVDU\GXHWRFXUU HQWRUIXWXUHSDQGHPLFUHODWHG
HPHUJHQF\UHVWULFWLRQVZKLFKPD\OHDGWRGHOD\VLQVFKHGXOHGI ROORZXSYLVLWV
x6XEMHFWVH[SHULHQFLQJDQDGYHUVH HYHQWUHODWHGWRFRQWDFWOHQV ZHDUPD\UHFHLYHGHO D\HGWUHDWPHQW
GXHWR&29,'UHVWULFWLRQV,QWKLVHYHQWDOODVVHVVPHQWVWK DWFDQEHFRQGXFWHGYLUWXDOO\ZLOOEH
FRPSOHWHGE\WKHLQYHVWLJDWRUWRGHWHUPLQHWKHEHVWFRXUVHRIWUHDWPHQWIRUWKHVXEMHFWLQFOXGLQJ
DQXQVFKHGXOHGYLVLWXSWRGLVFRQWLQXDWLRQIURPWKHVWXG\DV DSSURSULDWH
,IDVWXG\VXEMHFWLVIRXQGWRKDYHFRQWUDFWHG&29,'GXULQJ SDUWLFLSDWLRQLQDVWXG\KHVKHZLOOEH
GLVFRQWLQXHGIURPWKHVWXG\DQGIROORZHGXQWLO&29,'$GYHUVH (YHQW$(UHVROXWLRQ
7RKHOSPLQLPL]HWKHDERYHSRWHQWLDOULVNV--9&,UHFRPPHQGUHYLHZLQJFRPSO\LQJZLWKORFDOVWDWH
DQGJRYHUQPHQWDOJXLGDQFHIRU&29,'ULVNV
--9&,ZLOOSURYLGHWKHIROORZLQJVWXG\VSHFLILFGRFXPHQWVZLWK ODQJXDJHSHUWDLQLQJWR&29,'ULVNV
,QIRUPHG&RQVHQW 
:LOOLQFOXGHLQIRUPDWLRQFRQFHUQL QJWKHVWXG\DVVRFLDWHGULVNV UHODWHGWRWKH&29,'SDQGHPLF
LQEROGIRQWDQGRUER[HGRQWKHILUVWSDJHRIWKH,QIRUPHG&RQ VHQWGRFXPHQW

CR-6400, v 4.0  
Page 172 of 180JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation  
Document Type:  Work Instruction  
Document Number:  VWI-0081 Revision Number:  1 
 
Page 5 of 9 RESOURCE LINKS  
 
• OSHA Training  
https://www.osha.gov/SLTC/covid- 19/controlprevention.html    
 
Personal Protective Equipment ( PPE) Training 
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using- ppe.html 
 
• I&R Training  
ACUVUE® LensAssist: https://www.acuvue.com/lensassist     
 
• Clinic Preparedness Guides  
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clinic -preparednesshtml   
AOA: https://aoa.uberflip.com/i/1240437- aoa-guidance-for-re-opening-practices-covid·19/1?m4=   
American Optometric Association: https://www.aoa.org/optometry- practice-reactivation -preparedness -
guide 
 
• ln-Office Disinfection of Multi- Patient Use Diagnostic Contact [CONTACT_93957]://www.gpli.info/wp -content/uploads/2020/03/2020- 01-15-in-office-disinfecting -of-diagnostic -
lenses.pdf   
 
4.1.3 Protocol Compliance Investigator(s) Signature [CONTACT_3490] :  
Will include a statement indicating  that the Principal Investigator ( PI) agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s  for COVID -[ADDRESS_506765] read the suggested guidance provided by [CONTACT_19610] -19 risk mitigation,  
(COVID- 19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks. 
4.1.4 Study Site Initiation Training Slides :  
Will include suggestions to help mitigate potential transmission of COVID -19.  Suggestions may 
include maintaining social distancing in the clinical site by [CONTACT_35587],  
wearing proper PPEs, frequent disinfection, and installing shields on the slit lamp and other 
applicable equipment . 
5.[ADDRESS_506766] VISITS  
Potential disruptions to the study may be necessary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.   
Subjects may be delayed in being seen for study follow up visit(s), for example due to  COVID-[ADDRESS_506767]’s  concerns or fears about COVID -[ADDRESS_506768] during remote assessments 
may include:  
CR-6400, v 4.0
 
Page 175 of 180
JJVC CONFIDENTIAL

7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU 9:, 5HYLVLRQ1XPEHU
3DJHRI  7KHVSRQVRUZLOOFRQWLQXHWRPRQLWRUWKHFRQGXFWDQGSURJUHVVR IWKHFOLQLFDOVWXG\DQGDQ\FKDQJHVZLOOEH
FRPPXQLFDWHGWRWKHVLWHVDQGWR WKHKHDOWKDXWKRULWLHVDFFRUGL QJWRORFDOJXLGDQFH
,IDSDUWLFLSDQWKDVWHVWHGSRVLWLYHIRU&29,'WKHLQYHVWLJ DWRUVKRXOGFRQWDFWWKHVSRQVRU¶VUHVSRQVLEOH
PHGLFDOPRQLWRUWRGLVFXVVLQLWLDOSODQVIRUVWXG\LQWHUYHQWLRQ DQGIROORZXS7KHPHGLFDOPRQLWRUZLOO
QRWLI\WKH6DIHW\0DQDJHPHQW7HDP RIDQ\VXEMHFWVWKDWKDYHU HSRUWHG³&29,'´³$V\PSWRPDWLF
&29,'´RU³6XVSHFWHG&29,'´DGYHUVHHYHQWVZLWKLQKRX UVRIWKHQRWLILFDWLRQ
0RGLILFDWLRQVPDGHWRWKHVWXG\FRQGXFWDVDUHVXOWRIWKH&29, 'SDQGHPLFZLOOEHVX[COMPANY_003]UL]HGLQWKH
FOLQLFDOVWXG\UHSRUW
&29,'VFUHHQLQJSURFHGXUHVWKDWPD\EHPDQGDWHGE\ORFDOKHD OWKFDUHV\VWHPVGRQRWQHHGWREH
UHSRUWHGDVDQDPHQGPHQWWRWKHSURWRFROHYHQLIGRQHGXULQJFOLQLFDOVWXG\YLVLWV
0RQLWRULQJ9LVLWV
:KHQRQVLWHPRQLWRULQJE\WKHVSRQVRULVQRWIHDVLEOHWKHVSR QVRU¶VVLWHPRQLWRUZLOOFRQWDFWWKHVWXG\
VLWHWRVFKHGXOHUHPRWHYLVLWV,QVXFKFDVHVRQVLWHPRQLWRUL QJYLVLWVZLOOUHVXPHZKHQIHDVLEOHZLWK
LQFUHDVHGIUHTXHQF\WRDGGUHVVWKHVRXUFHGDWDYHULILFDWLRQEDF NORJ
(YHQZLWKVWDIILQJOLPLWDWLRQVGXULQJWKLV&29,'SDQGHPLFD OOURXWLQHRSHUDWLRQVUHODWHGWRFOLQLFDO
WULDOVVKRXOGEHZHOOGRFXPHQWHGDQGDUFKLYHGDVSDUWRIVWDQGD UGSURFHVV:KHQFRQGLWLRQVSHUPLWDOO
SDUWLHVLQYROYHGLQWKLVFOLQLFDOWULDOVKRXOGFRPPXQLFDWHUHOHYDQWLQIRUPDWLRQLQDWLPHO\PDQQHUVRWKDW
DOOUHOHYDQWSDUWLHVUHPDLQVXIILFLHQWO\LQIRUPHG
6WXG\6LWH,QLWLDWLRQ
'XULQJWKHSHULRGWKDWWKLV:RUN,QVWUXFWLRQLVLQHIIHFW6LWH ,QLWLDWLRQ0HHWLQJVDQGWUDLQLQJRI
VWXG\VLWHVWDIIZLOOEHFRQGXFWHGUHPRWHO\7KH--9&,VWXG\WH DPZLOOFRQGXFWWUDLQLQJYLD6N\SH
=RRP0LFURVRIW7HDPVRUVLPLODUVRIWZDUHDVZHOODVXWLOL]HRQ OLQHWUDLQLQJPDWHULDOVDVDSSOLFDEOH
6WXG\VLWHWUDLQLQJZLOOEHGRFXP HQWHGXWLOL]LQJ6LWH,QLWLDWLR Q5HSRUW)RUP&RQWURO1R 9&7
SHU6WXG\6LWH,QLWLDWLRQ)RUP&RQWURO1R 9&&/ 
2QVLWHYLVLWVPD\EHFRQVLGHUHGZKHQIRUH[DPSOHKDQGVRQWUDLQLQJRUHYDOXDWLRQRIVLWHIDFLOLWLHV
LVUHTXLUHG:KLOHRQVLWHWKH&OLQLFDO5HVHDUFK$VVRFLDWH&5 $ZLOOIROORZDOOORFDOVWDWHDQG
JRYHUQPHQWDOSROLFLHVIRU&29,' 5LVN0LWLJDWLRQLQFOXGLQJV RFLDOGLVWDQFLQJZHDULQJRI33(
HWFDVDSSOLFDEOHIRUWKHORFDWLRQRIWKHVWXG\VLWH
,QWHULP0RQLWRULQJ9LVLWVLIDSSOLFDEOH
'XULQJWKHSHULRGWKDWWKLV:RUN,QVWUXFWLRQLVLQHIIHFW,QWH ULP0RQLWRULQJ2QVLWHYLVLWVZLOOEH
NHSWWRDPLQLPXPDQGLQFOXGHRQO\WKRVHWDVNVWKDWWKH&5$FDQ QRWSHUIRUPUHPRWHO\HJVRXUFH
GRFXPHQWYHULILFDWLRQWHVWDUWLFOHUHFRQFLOLDWLRQHWF
7RHQVXUHGDWDLQWHJULW\GXULQJWKHFRQGXFWRIDOO--9&VWXGLHV FOLQLFDOVWXG\W HDPVZLOOIROORZWKH
VWXG\VSHFLILF&OLQLFDO0RQLWRULQJ3ODQ)RUP&RQWURO1R 9&7 
:KLOHRQVLWHWKH&5$ZLOOIROORZDOOORFDOVWDWHDQGJRYHUQ PHQWDOSROLFLHVIRU&29,'5LVN
0LWLJDWLRQLQFOXGLQJVRFLDOGLVWDQFLQJZHDULQJRI33(HWFD VDSSOLFDEOHIRUWKHORFDWLRQRIWKH
VWXG\VLWH
CR-6400, v 4.0  
Page 177 of 180JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation  
Document Type:  Work Instruction  
Document Number:  VWI-0081 Revision Number:  1 
 
Page 8 of 9 6.1.3 Study Site Closure:   
During the period that this Work Instruction is in effect, the duration of the Study Site Closure Visit 
will be lim ited to tasks that the CRA cannot perform remotely (e.g., source document verification, 
test article final reconciliation and return,  etc.).   
   
CR-6400, v 4.0
 
Page 178 of 180
JJVC CONFIDENTIAL

Title: Guidelines for COVID-19 Risk Mitigation  
Document Type:  Work Instruction  
Document Number:  VWI-0081 Revision Number:  1 
 
Page 9 of 9 Attachment A: Study Site Correspondenc e 
 
XXXX XX, 2020  
   
Re: COVID- 19 Mitigation Plan, << CR-xxxx/protocol title>>  
 
 Dear <<Principle Investigator>> and Study Team,  
 Coronavirus (COVID -19) has impacted several communities and business activities over the past several months. 
While we work toward the successful conduct of clinical studies, our commitment continues to be the safety of patients, healthcare professionals, and to our communities.  
 Therefore, we would like to share the following revisions/additions related to the above referenced [COMPANY_012] Vision Care company sponsored clinical trial(s) you are currently working on or considering participation 
within.  
 
Protocol:  
• Guidelines for COVID -19 Risk Mitigation provided in the Appendix section.  
Protocol Signature [CONTACT_3490]:  
 
• Will include a statement indicating the Principle Investigator agrees to conduct the study in compliance 
with all local, state, and governmental guidelines for COVID -19 risk mitig ation. 
 
Informed Consent:  
  
• Will include information concerning the study- associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.  
COVID-[ADDRESS_506769] for Clinical Studies: 
• Will include COVID -[ADDRESS_506770] with your respective 
[COMPANY_012] clinical study team ( Clinical Research Associate (CRA ), Lead CRA or Study Managers).   
 
Thank you for you r continued engagement, collaboration, and dedication to your study subjects during this 
challenging time.  
 
 
Please file this letter in your site file study correspondence.  
 
 
CR-6400, v 4.0
 
Page 179 of 180
JJVC CONFIDENTIAL

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_93962]: CR-6400 Protocol Title: Clinical Evaluation of a Daily Wear Reusable 
Multifocal Optical Design in a Presby[CONTACT_402163]:  4.[ADDRESS_506771] this study according to ISO [ZIP_CODE],1 GCP and ICH guidelines ,2 the Declaration of 
Helsinki,3 [LOCATION_002] (US) Code of Federal Regulations (CFR),4 and the pertinent individual country 
laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The 
Principal Investigator [INVESTIGATOR_19539], including Sub -
Investigators adhere to all ICH2 regulations and GCP guidelines regarding clinical trials during and 
after study completion.  
 
I will assure that no deviation from or changes to the protocol wi ll take place without prior agreement 
from the Sponsor and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.  
 I am responsible for ensuring that all clinical  site personnel including Sub- Investigators adhere to all 
ICH
[ADDRESS_506772] read the suggested guidance provided by [CONTACT_19610] -19 risk mit igation, 
(COVID- 19 Work Instruction in the Appendix of this protocol). I agree to conduct the study in 
compliance with all local, state, and governmental guidelines for COVID- 19 risk mitigation.  
 
Principal 
Investigator:   
   
 [INVESTIGATOR_71160] (Printed)    
 
Institution/Site:     
 Institution/Site Name  
 
   
 [CONTACT_16277]/Site Address    
 
CR-6400, v 4.0
 
Page 180 of 180
JJVC CONFIDENTIAL
